Lakefront Biotherapeutics NV (LKFT)
NASDAQ: LKFT · Real-Time Price · USD
27.21
-0.43 (-1.56%)
Jul 31, 2026, 4:00 PM EDT - Market closed
LKFT Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,092 | 1,166 | 316.42 | 287 | 277.38 | 280.46 | |
Revenue Growth | 234.71% | 268.41% | 10.25% | 3.47% | -1.10% | -47.11% |
Cost of Revenue | 20.81 | 29.74 | 34.86 | - | - | - |
Gross Profit | 1,071 | 1,136 | 281.56 | 287 | 277.38 | 280.46 |
Selling, General & Admin | 145.14 | 153.43 | 134.44 | 133.97 | 138.64 | 131.52 |
Research & Development | 307.63 | 459.42 | 335.46 | 241.29 | 269.8 | 320.5 |
Other Operating Expenses | - | 228.11 | - | - | - | - |
Total Operating Expenses | 452.77 | 840.97 | 469.9 | 375.26 | 408.43 | 452.02 |
Operating Income | 390.04 | 295.04 | -188.34 | -88.26 | -131.06 | -171.57 |
Interest Income | 49.04 | 48.05 | 91.13 | 80.25 | 18.56 | 3.06 |
Interest Expense | -2.22 | -2.86 | -1.67 | -2.61 | -9.85 | -12.35 |
Other Non-Operating Income (Expense) | 34.33 | -39.36 | 95.8 | 16.25 | 51.5 | 61.46 |
Total Non-Operating Income (Expense) | 81.15 | 5.83 | 185.25 | 93.89 | 60.21 | 52.17 |
Pretax Income | 471.19 | 300.87 | -3.09 | 5.63 | -70.85 | -119.4 |
Provision for Income Taxes | 16.74 | 18.62 | 1.8 | -9.61 | -0.57 | -1.39 |
Net Income | 454.46 | 282.25 | -4.89 | 15.24 | -70.28 | -118.01 |
Earnings From Discontinued Operations | 0.85 | 1.39 | 75.36 | 215.69 | -146.57 | 17.56 |
Net Income to Common | 488.78 | 320.88 | 74.08 | 211.7 | -217.99 | -103.23 |
Net Income Growth | - | 333.15% | -65.01% | - | - | - |
Shares Outstanding (Basic) | 66 | 66 | 66 | 66 | 66 | 66 |
Shares Outstanding (Diluted) | 66 | 66 | 66 | 66 | 66 | 66 |
Shares Change | -0.04% | - | 0.02% | 0.28% | 0.30% | 0.65% |
EPS (Basic) | 7.42 | 4.87 | 1.12 | 3.21 | -3.32 | -1.58 |
EPS (Diluted) | 7.42 | 4.87 | 1.12 | 3.21 | -3.32 | -1.58 |
EPS Growth | - | 334.82% | -65.11% | - | - | - |
Free Cash Flow | -310.33 | -271.16 | -336.75 | -424.68 | -527.93 | -558.03 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -4.71 | -4.11 | -5.11 | -6.45 | -8.04 | -8.52 |
Gross Margin | 98.09% | 97.45% | 88.98% | 100.00% | 100.00% | 100.00% |
Operating Margin | 35.73% | 25.31% | -59.52% | -30.75% | -47.25% | -61.17% |
Profit Margin | 41.63% | 24.21% | -1.54% | 5.31% | -25.34% | -42.08% |
FCF Margin | -28.43% | -23.26% | -106.42% | -147.97% | -190.33% | -198.97% |
EBITDA | 390.04 | 350.91 | -188.34 | -44.62 | -65.49 | -136.93 |
EBITDA Margin | 35.73% | 30.10% | -59.52% | -15.55% | -23.61% | -48.82% |
EBIT | 390.04 | 295.04 | -188.34 | -88.26 | -131.06 | -171.57 |
EBIT Margin | 35.73% | 25.31% | -59.52% | -30.75% | -47.25% | -61.17% |
Effective Tax Rate | 3.55% | 6.19% | -58.44% | -170.90% | 0.81% | 1.16% |